Carmen González Macías
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carmen González Macías has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Juan Jesús Fernández Alba
Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA)
2 shared publications - Alfonso Sierra-Padilla
Institute of Research on Electron Microscopy and Materials (IMEYMAT), Department of Analytical Chemistry, Faculty of Sciences, Campus de Excelencia Internacional del Mar (CEIMAR), University of Cadiz, Campus Universitario de Puerto Real, 11510, Spain
1 shared publication - Cristina Casals
ExPhy Research Group, Department of Physical Education, Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), 11009 Cádiz, Spain
1 shared publication - Daniel Fatela-Cantillo
Department of Laboratory Medicine, Virgen del Rocío University Hospital, 41013 Seville, Spain
1 shared publication - Dolores Bellido-Milla
Institute of Research on Electron Microscopy and Materials (IMEYMAT), Department of Analytical Chemistry, Faculty of Sciences, Campus de Excelencia Internacional del Mar (CEIMAR), University of Cadiz, Campus Universitario de Puerto Real, Polígono del Río San Pedro S/N, Puerto Real, 11510 Cádiz, Spain
1 shared publication - Jesús Gustavo Ponce-González
ExPhy Research Group, Department of Physical Education, Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), Universidad de Cádiz, 11519 Cádiz, Spain
1 shared publication
Latest Publications
- Open Access
- 26 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2718
Differential Serum MicroRNA Profiling in Benign and Malignant Ovarian Tumours: An Exploratory Study Identifying hsa-miR-200c-3p as a Candidate Diagnostic Biomarker
Background/Objectives: Preoperative discrimination of benign from malignant adnexal masses remains a major clinical challenge, and circulating microRNAs (miRNAs) are candidate non-invasive biomarkers. This exploratory, hypothesis-generating study—not a diagnostic validation study—evaluated serum hsa-miR-200c-3p as a candidate diagnostic biomarker for ovarian malignancy. Methods: Serum from 39 women with an adnexal mass and a surgical indication (20 benign, 19 malignant), all with histological confirmation, was analysed. Of 179 assayed miRNAs, 178 were tested for differential expression (miR-103a-3p as endogenous reference) using the Mann–Whitney U test with Benjamini–Hochberg false-discovery-rate (FDR) correction; hsa-miR-200c-3p, a pre-specified miR-200 family candidate, was evaluated by ROC analysis and compared with, and adjusted for, CA 125, HE4 and age. Results: The malignant group was substantially older and more frequently postmenopausal. Thirty-eight miRNAs were significant after FDR correction; hsa-miR-200c-3p was up-regulated in malignancy. In the complete-case analysis restricted to the 35 participants with a detectable marker (20 benign, 15 malignant), the AUC was 0.893 (95% CI 0.76–0.99); however, four high-grade serous carcinomas showed undetectable serum hsa-miR-200c-3p, and when these were included and imputed as low expression (all-case analysis, n = 39) the AUC fell to 0.705 (95% CI 0.51–0.88). hsa-miR-200c-3p did not demonstrate statistically superior performance to HE4 (AUC 0.93) or CA 125 (0.89), with overlapping confidence intervals; any incremental value beyond established markers and age was modest and exploratory. Conclusions: Serum hsa-miR-200c-3p is a preliminary candidate that requires prospective, age-matched, adequately powered validation with pre-specified assays and analysis plans.
- 26 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2718
Open AccessDifferential Serum MicroRNA Profiling in Benign and Malignant Ovarian Tumours: An Exploratory Study Identifying hsa-miR-200c-3p as a Candidate Diagnostic Biomarker
Background/Objectives: Preoperative discrimination of benign from malignant adnexal masses remains a major clinical challenge, and circulating microRNAs (miRNAs) are candidate non-invasive biomarkers. This exploratory, hypothesis-generating study—not a diagnostic validation study—evaluated serum hsa-miR-200c-3p as a candidate diagnostic biomarker for ovarian malignancy. Methods: Serum from 39 women with an adnexal mass and a surgical indication (20 benign, 19 malignant), all with histological confirmation, was analysed. Of 179 assayed miRNAs, 178 were tested for differential expression (miR-103a-3p as endogenous reference) using the Mann–Whitney U test with Benjamini–Hochberg false-discovery-rate (FDR) correction; hsa-miR-200c-3p, a pre-specified miR-200 family candidate, was evaluated by ROC analysis and compared with, and adjusted for, CA 125, HE4 and age. Results: The malignant group was substantially older and more frequently postmenopausal. Thirty-eight miRNAs were significant after FDR correction; hsa-miR-200c-3p was up-regulated in malignancy. In the complete-case analysis restricted to the 35 participants with a detectable marker (20 benign, 15 malignant), the AUC was 0.893 (95% CI 0.76–0.99); however, four high-grade serous carcinomas showed undetectable serum hsa-miR-200c-3p, and when these were included and imputed as low expression (all-case analysis, n = 39) the AUC fell to 0.705 (95% CI 0.51–0.88). hsa-miR-200c-3p did not demonstrate statistically superior performance to HE4 (AUC 0.93) or CA 125 (0.89), with overlapping confidence intervals; any incremental value beyond established markers and age was modest and exploratory. Conclusions: Serum hsa-miR-200c-3p is a preliminary candidate that requires prospective, age-matched, adequately powered validation with pre-specified assays and analysis plans.
- Open Access
- 27 December 2025
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (1) , 48
Advancement in continuous lactate determination in untreated human serum: multipolymer-based amperometric biosensor coupled with a low-cost 3D-printed microfluidic cell
Enzyme saturation in biosensing has been established as a main hindrance in lactate monitoring due to the high concentration of this species in biological samples. In this paper, a Sonogel–carbon transducer has been used for the fabrication of an amperometric biosensor for lactate (LA) determination. The sensor was constructed by immobilizing lactate oxidase as the bioreceptor and coating the electrode surface with multipolymer layers to minimize enzyme saturation and improve operational stability. This biosensor shows adequate sensitivity (1.74 µA mM − 1 cm -2 ) in a linear working range from 0.2 mM to 20 mM, suitable for physiological lactate concentrations in biofluids. The response of the biosensor was studied in physiological medium using several potential interferents (glucose, uric acid, dopamine, ascorbic acid, KCl, NaCl, CaCl 2 and BSA), demonstrating negligible interference from these common electroactive species. A microfluidic cell was designed and fabricated using polyethylene terephthalate glycol (PETG) through a rapid and low-cost 3D printing process. Finally, the prepared microfluidic cell was applied to lactate monitoring in flow regime using the biosensor with both synthetic and real untreated human serum samples, showing excellent correlation with two standard reference techniques and confirming its reliability. These results highlight the potential of the proposed microfluidic amperometric biosensor as a robust, real-time tool for biomedical lactate monitoring. Graphical Abstract
- 27 December 2025
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (1) , 48
Open AccessAdvancement in continuous lactate determination in untreated human serum: multipolymer-based amperometric biosensor coupled with a low-cost 3D-printed microfluidic cell
Enzyme saturation in biosensing has been established as a main hindrance in lactate monitoring due to the high concentration of this species in biological samples. In this paper, a Sonogel–carbon transducer has been used for the fabrication of an amperometric biosensor for lactate (LA) determination. The sensor was constructed by immobilizing lactate oxidase as the bioreceptor and coating the electrode surface with multipolymer layers to minimize enzyme saturation and improve operational stability. This biosensor shows adequate sensitivity (1.74 µA mM − 1 cm -2 ) in a linear working range from 0.2 mM to 20 mM, suitable for physiological lactate concentrations in biofluids. The response of the biosensor was studied in physiological medium using several potential interferents (glucose, uric acid, dopamine, ascorbic acid, KCl, NaCl, CaCl 2 and BSA), demonstrating negligible interference from these common electroactive species. A microfluidic cell was designed and fabricated using polyethylene terephthalate glycol (PETG) through a rapid and low-cost 3D printing process. Finally, the prepared microfluidic cell was applied to lactate monitoring in flow regime using the biosensor with both synthetic and real untreated human serum samples, showing excellent correlation with two standard reference techniques and confirming its reliability. These results highlight the potential of the proposed microfluidic amperometric biosensor as a robust, real-time tool for biomedical lactate monitoring. Graphical Abstract